Sign inJoin waitlistJoin the waitlist

AH

Andrea Harzstark

Physician · Permanente Medical Group Inc

Credentials: · · ·

History

Permanente Medical Group Inc
2019–Present

University of California-San Francisco
2005–2007
Santa Monica-UCLA Medical Center
2002–2005
Stanford University School of Medicine
1998–2002

Research

Metabolic imaging of patients with prostate cancer using hyperpolarized [1-¹³C]pyruvate
Science Translational Medicine · 2013 · 1,052 citations
Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study
Annals of Oncology · 2013 · 442 citations
Platinum-based chemotherapy for variant castrate-resistant prostate cancer
Clinical Cancer Research · 2013 · 389 citations

Eric Small
17 papers
CR
Charles Ryan
14 papers
JR
Jonathan Rosenberg
6 papers
Maha Hussain
6 papers
NV
Nicholas Vogelzang
6 papers
Terence Friedlander
6 papers · 2 as a fellow
DS
David Smith
5 papers
Lawrence Fong
5 papers
Primo Lara
5 papers
Paul Corn
4 papers
Alan Bryce
3 papers
CH
Celestia Higano
3 papers

Clinical trials

Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy
Principal investigator · Completed · Phase 1, Phase 2
National Cancer Institute (NCI)
2006–2010
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
Study chair · Withdrawn · Phase 2
Andrea Harzstark
2012–2016
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2039
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Site PI · Recruiting · Phase 2, Phase 3
National Cancer Institute (NCI)
2024–2030